How long can patients with advanced cholangiocarcinoma take pemetinib/pemetinib targeted drugs?

Pemetinib/Pemetinib is a targeted drug targeting FGFR (fibroblast growth factor receptor). It is mainly used to treat patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. These drugs inhibit the proliferation and growth of tumor cells by inhibiting the activity of FGFR, thereby providing new treatment options for patients with cholangiocarcinoma.

In clinical trials, pemetinib/pemetinib has shown certain efficacy. For example, in a clinical trial for patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement, the disease control rate of pemetinib was as high as 82%, with a median progression-free survival (PFS) was 6.9 months, and the median overall survival (OS) was 21.1 months. This means that for this group of patients, the use of pemetinib can significantly prolong their survival.

These numbers are just average results from clinical trials and cannot be directly applied to every patient. The patient's survival period is affected by many factors, including but not limited to the malignancy of the tumor, the type of genetic mutation, the efficacy of targeted drugs, the patient's physical condition, and adverse reactions during treatment.

Therefore, for patients with advanced cholangiocarcinoma, how long the pemetinib targeted drug can last is a question that varies from person to person. Some patients may have a longer survival period, while some patients may have a shorter survival period due to high malignancy of the tumor or drug intolerance.

Although targeted drugs such as pemetinib/pemetinib provide new treatment options for patients with cholangiocarcinoma, they are not a panacea. In the treatment of cholangiocarcinoma, traditional treatment methods such as surgery, radiotherapy, and chemotherapy still occupy an important position. Therefore, when formulating a treatment plan, doctors need to conduct a comprehensive assessment based on the patient's specific situation and choose the most suitable treatment method for the patient.